Moussa Laanani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Moussa Laanani has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
Joël Coste
Biostatistics and Epidemiology Department, Cochin Hospital, Assistance Publique – Hôpitaux de Paris (AP-HP), Paris Cité University, Paris, France
5 shared publicationsGrégoire Rey
French Centre for Epidemiology on Medical Causes of Death (CépiDc-Inserm), Le Kremlin-Bicêtre, France
3 shared publicationsAlain Weill
Epiphare (French National Medicines Agency ANSM and French National Health Insurance CNAM), Saint-Denis, France
2 shared publications- Alain Weill
EPI‐PHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products [ANSM] French National Health Insurance [CNAM]) Saint‐Denis France
2 shared publications Eric Jougla
CépiDc Inserm (Epidemiological Centre on Medical Causes of Death, National Institute of Health and Medical Research), Le Kremlin-Bicêtre, France
2 shared publicationsFabrice Jollant
Université Paris-Saclay & CHU Bicêtre, AP-HP, Le Kremlin-Bicêtre, France
2 shared publications
Latest Publications
- 4 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Étude des relations entre l’état de santé, sa prise en charge et le décès par suicide à partir du Système national des données de santé
Le suicide représente un problème de santé publique majeur en France avec près de 10 000 décès prématurés chaque année. L'étude des déterminants du suicide est complexe. Il s'agit d’un phénomène plurifactoriel, pouvant être influencé par des éléments personnels et/ou environnementaux, bio-médicaux et/ou socio-économiques. La présence de pathologies (psychiatriques ou somatiques) chez l'individu joue un rôle important. Les pathologies psychiatriques peuvent se compliquer de processus suicidaires (idées suicidaires, pouvant être suivies de comportements suicidaires, puis d'un décès par suicide). Pour les pathologies somatiques, la maladie peut impacter de manière importante la qualité de vie de l'individu, favorisant des processus suicidaires, et ainsi des décès par suicide. Des troubles psychiatriques peuvent ainsi compliquer les maladies somatiques, et constituer une étape vers la survenue de processus suicidaires. Les maladies somatiques peuvent également survenir chez des individus souffrant de troubles psychiatriques, et favoriser le déclenchement de processus suicidaires. Pour les pathologies psychiatriques comme somatiques, les processus suicidaires peuvent également être la conséquence d'effets indésirables des traitements médicamenteux. Il est alors souvent difficile de dénouer le rôle du traitement et de la pathologie traitée. Ce travail de thèse visait à étudier les relations complexes entre pathologies et suicide, à partir des données du Système national des données de santé (SNDS).
- 4 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Étude des relations entre l’état de santé, sa prise en charge et le décès par suicide à partir du Système national des données de santé
Le suicide représente un problème de santé publique majeur en France avec près de 10 000 décès prématurés chaque année. L'étude des déterminants du suicide est complexe. Il s'agit d’un phénomène plurifactoriel, pouvant être influencé par des éléments personnels et/ou environnementaux, bio-médicaux et/ou socio-économiques. La présence de pathologies (psychiatriques ou somatiques) chez l'individu joue un rôle important. Les pathologies psychiatriques peuvent se compliquer de processus suicidaires (idées suicidaires, pouvant être suivies de comportements suicidaires, puis d'un décès par suicide). Pour les pathologies somatiques, la maladie peut impacter de manière importante la qualité de vie de l'individu, favorisant des processus suicidaires, et ainsi des décès par suicide. Des troubles psychiatriques peuvent ainsi compliquer les maladies somatiques, et constituer une étape vers la survenue de processus suicidaires. Les maladies somatiques peuvent également survenir chez des individus souffrant de troubles psychiatriques, et favoriser le déclenchement de processus suicidaires. Pour les pathologies psychiatriques comme somatiques, les processus suicidaires peuvent également être la conséquence d'effets indésirables des traitements médicamenteux. Il est alors souvent difficile de dénouer le rôle du traitement et de la pathologie traitée. Ce travail de thèse visait à étudier les relations complexes entre pathologies et suicide, à partir des données du Système national des données de santé (SNDS).
- Open Access
- 14 December 2023
- Published by Springer Nature in Population Health Metrics
- Vol. 21 (1) , 1-12
Collider and reporting biases involved in the analyses of cause of death associations in death certificates: an illustration with cancer and suicide
Background: Mortality data obtained from death certificates have been studied to explore causal associations between diseases. However, these analyses are subject to collider and reporting biases (selection and information biases, respectively). We aimed to assess to what extent associations of causes of death estimated from individual mortality data can be extrapolated as associations of disease states in the general population. Methods: We used a multistate model to generate populations of individuals and simulate their health states up to death from national health statistics and artificially replicate collider bias. Associations between health states can then be estimated from such simulated deaths by logistic regression and the magnitude of collider bias assessed. Reporting bias can be approximated by comparing the estimates obtained from the observed death certificates (subject to collider and reporting biases) with those obtained from the simulated deaths (subject to collider bias only). As an illustrative example, we estimated the association between cancer and suicide in French death certificates and found that cancer was negatively associated with suicide. Collider bias, due to conditioning inclusion in the study population on death, increasingly downwarded the associations with cancer site lethality. Reporting bias was much stronger than collider bias and depended on the cancer site, but not prognosis. Results: The magnitude of the biases ranged from 1.7 to 9.3 for collider bias, and from 4.7 to 64 for reporting bias. Conclusions: These results argue for an assessment of the magnitude of both collider and reporting biases before performing analyses of cause of death associations exclusively from mortality data. If these biases cannot be corrected, results from these analyses should not be extrapolated to the general population.
- 14 December 2023
- Published by Springer Nature in Population Health Metrics
- Vol. 21 (1) , 1-12
Open AccessCollider and reporting biases involved in the analyses of cause of death associations in death certificates: an illustration with cancer and suicide
Background: Mortality data obtained from death certificates have been studied to explore causal associations between diseases. However, these analyses are subject to collider and reporting biases (selection and information biases, respectively). We aimed to assess to what extent associations of causes of death estimated from individual mortality data can be extrapolated as associations of disease states in the general population. Methods: We used a multistate model to generate populations of individuals and simulate their health states up to death from national health statistics and artificially replicate collider bias. Associations between health states can then be estimated from such simulated deaths by logistic regression and the magnitude of collider bias assessed. Reporting bias can be approximated by comparing the estimates obtained from the observed death certificates (subject to collider and reporting biases) with those obtained from the simulated deaths (subject to collider bias only). As an illustrative example, we estimated the association between cancer and suicide in French death certificates and found that cancer was negatively associated with suicide. Collider bias, due to conditioning inclusion in the study population on death, increasingly downwarded the associations with cancer site lethality. Reporting bias was much stronger than collider bias and depended on the cancer site, but not prognosis. Results: The magnitude of the biases ranged from 1.7 to 9.3 for collider bias, and from 4.7 to 64 for reporting bias. Conclusions: These results argue for an assessment of the magnitude of both collider and reporting biases before performing analyses of cause of death associations exclusively from mortality data. If these biases cannot be corrected, results from these analyses should not be extrapolated to the general population.
- Open Access
- 31 March 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-12
Suicidal risk associated with finasteride versus dutasteride among men treated for benign prostatic hyperplasia: nationwide cohort study
Finasteride, a 5α-reductase inhibitor used in benign prostatic hyperplasia and androgenetic alopecia, has been associated with an increased suicidal risk, whereas it is unclear whether such risk is similar to that for another 5α-reductase inhibitor, dutasteride. We aimed to assess the risk of suicidal behaviours with finasteride relative to dutasteride. A nationwide cohort study was conducted using the French National Health Data System (SNDS). Men aged 50 years or older initiating finasteride 5 mg or dutasteride 0.5 mg in France between 01-01-2012 and 30-06-2016 were included and followed until outcome (suicide death identified from death certificate or self-harm hospitalisation), treatment discontinuation or switch, death, or 31-12-2016. Self-harm by violent means or resulting in admission to an intensive care unit were also examined. Cox proportional hazards models controlled for age and psychiatric and non-psychiatric conditions by inverse probability of treatment weighting (IPTW). Analyses were stratified according to psychiatric history. The study compared 69,786 finasteride new users to 217,577 dutasteride new users (median age: 72.0 years [Q1–Q3 = 64.5–80.2] vs. 71.1 [Q1–Q3 = 65.0–79.2]). During follow-up, 18 suicide deaths (0.57/1000 person-years) and 34 self-harm hospitalisations (1.08/1000) occurred among finasteride users versus 47 deaths (0.43/1000) and 87 hospitalisations (0.79/1000) among dutasteride users. Overall, finasteride was not associated with an increased risk of any suicidal outcome (IPTW-adjusted Hazard Ratio = 1.21 [95% Confidence Interval .87–1.67]), suicide death or self-harm hospitalisation. However, among individuals with a history of mood disorders, finasteride was associated with an increased risk of any suicidal outcome (25 versus 46 events; HR = 1.64 [95% CI 1.00–2.68]), suicide death (8 versus 10 events; HR = 2.71 [95% CI 1.07–6.91]), self-harm by violent means (6 versus 6 events; HR = 3.11 [95% CI 1.01–9.61]), and self-harm with admission to an intensive care unit (7 versus 5 events; HR = 3.97 [95% CI 1.26–12.5]). None of these risks was significantly increased among individuals without a psychiatric history. These findings do not support an increased risk of suicide with finasteride used in the treatment of benign prostatic hyperplasia. However, an increased risk cannot be excluded among men with a history of mood disorder, but this result based on a limited number of events should be interpreted with caution.
- 31 March 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-12
Open AccessSuicidal risk associated with finasteride versus dutasteride among men treated for benign prostatic hyperplasia: nationwide cohort study
Finasteride, a 5α-reductase inhibitor used in benign prostatic hyperplasia and androgenetic alopecia, has been associated with an increased suicidal risk, whereas it is unclear whether such risk is similar to that for another 5α-reductase inhibitor, dutasteride. We aimed to assess the risk of suicidal behaviours with finasteride relative to dutasteride. A nationwide cohort study was conducted using the French National Health Data System (SNDS). Men aged 50 years or older initiating finasteride 5 mg or dutasteride 0.5 mg in France between 01-01-2012 and 30-06-2016 were included and followed until outcome (suicide death identified from death certificate or self-harm hospitalisation), treatment discontinuation or switch, death, or 31-12-2016. Self-harm by violent means or resulting in admission to an intensive care unit were also examined. Cox proportional hazards models controlled for age and psychiatric and non-psychiatric conditions by inverse probability of treatment weighting (IPTW). Analyses were stratified according to psychiatric history. The study compared 69,786 finasteride new users to 217,577 dutasteride new users (median age: 72.0 years [Q1–Q3 = 64.5–80.2] vs. 71.1 [Q1–Q3 = 65.0–79.2]). During follow-up, 18 suicide deaths (0.57/1000 person-years) and 34 self-harm hospitalisations (1.08/1000) occurred among finasteride users versus 47 deaths (0.43/1000) and 87 hospitalisations (0.79/1000) among dutasteride users. Overall, finasteride was not associated with an increased risk of any suicidal outcome (IPTW-adjusted Hazard Ratio = 1.21 [95% Confidence Interval .87–1.67]), suicide death or self-harm hospitalisation. However, among individuals with a history of mood disorders, finasteride was associated with an increased risk of any suicidal outcome (25 versus 46 events; HR = 1.64 [95% CI 1.00–2.68]), suicide death (8 versus 10 events; HR = 2.71 [95% CI 1.07–6.91]), self-harm by violent means (6 versus 6 events; HR = 3.11 [95% CI 1.01–9.61]), and self-harm with admission to an intensive care unit (7 versus 5 events; HR = 3.97 [95% CI 1.26–12.5]). None of these risks was significantly increased among individuals without a psychiatric history. These findings do not support an increased risk of suicide with finasteride used in the treatment of benign prostatic hyperplasia. However, an increased risk cannot be excluded among men with a history of mood disorder, but this result based on a limited number of events should be interpreted with caution.
- Open Access
- 20 June 2022
- Published by Wiley in European Journal of Neurology
- Vol. 29 (9) , 2801-2809
Risk of intracranial meningioma with three potent progestogens: A population‐based case–control study
Background and purpose: A dose‐dependent association between the use of cyproterone acetate (CPA) and intracranial meningioma has been identified but data for other potent progestogens are scarce. The association was assessed between intracranial meningioma surgery and exposure to three potent progestogens: CPA (≥25 mg/day), nomegestrol acetate (NOMAC) (3.75–5 mg/day) and chlormadinone acetate (CMA) (2–10 mg/day).Methods: In this nationwide population‐based case–control study, cases underwent surgery for intracranial meningioma in France from 2009 to 2018. They were matched to five control subjects for sex, year of birth and area of residence. Progestogen exposure was defined as progestogen use within the year before surgery for cases or the same date for their controls.Results: In total, 25,216 cases were included (75% women, median age 58 years). Progestogen exposure was noted for 9.9% of cases (2497/25,216) and 1.9% (2382/126,080) of controls, with an odds ratio (OR) of 6.7 (95% confidence interval [CI] 6.3–7.1). The OR was 1.2 (1.0–1.4) for short‐term use (<1 year) and 9.5 (8.8–10.2) for prolonged use. A strong association was identified for prolonged use of CPA (OR = 22.7, 95% CI 19.5–26.4), NOMAC (OR = 6.5, 95% CI 5.8–7.2) and CMA (OR = 4.7, 95% CI 4.5–5.3). Progestogen exposure increased the risk of meningioma for all histological grades and anatomical sites, particularly for the anterior and middle skull base: OR = 35.7 (95% CI 26.5–48.2) and 23.9 (95% CI 17.8–32.2) for CPA. The estimated number of attributable cases was 2124 (95% CI 2028–2220) (212/year).Conclusion: A strong association between prolonged exposure to potent progestogens and surgery for meningioma was observed. The risk increased from CMA to NOMAC to CPA. Individuals should be informed of this risk.
- 20 June 2022
- Published by Wiley in European Journal of Neurology
- Vol. 29 (9) , 2801-2809
Open AccessRisk of intracranial meningioma with three potent progestogens: A population‐based case–control study
Background and purpose: A dose‐dependent association between the use of cyproterone acetate (CPA) and intracranial meningioma has been identified but data for other potent progestogens are scarce. The association was assessed between intracranial meningioma surgery and exposure to three potent progestogens: CPA (≥25 mg/day), nomegestrol acetate (NOMAC) (3.75–5 mg/day) and chlormadinone acetate (CMA) (2–10 mg/day).Methods: In this nationwide population‐based case–control study, cases underwent surgery for intracranial meningioma in France from 2009 to 2018. They were matched to five control subjects for sex, year of birth and area of residence. Progestogen exposure was defined as progestogen use within the year before surgery for cases or the same date for their controls.Results: In total, 25,216 cases were included (75% women, median age 58 years). Progestogen exposure was noted for 9.9% of cases (2497/25,216) and 1.9% (2382/126,080) of controls, with an odds ratio (OR) of 6.7 (95% confidence interval [CI] 6.3–7.1). The OR was 1.2 (1.0–1.4) for short‐term use (<1 year) and 9.5 (8.8–10.2) for prolonged use. A strong association was identified for prolonged use of CPA (OR = 22.7, 95% CI 19.5–26.4), NOMAC (OR = 6.5, 95% CI 5.8–7.2) and CMA (OR = 4.7, 95% CI 4.5–5.3). Progestogen exposure increased the risk of meningioma for all histological grades and anatomical sites, particularly for the anterior and middle skull base: OR = 35.7 (95% CI 26.5–48.2) and 23.9 (95% CI 17.8–32.2) for CPA. The estimated number of attributable cases was 2124 (95% CI 2028–2220) (212/year).Conclusion: A strong association between prolonged exposure to potent progestogens and surgery for meningioma was observed. The risk increased from CMA to NOMAC to CPA. Individuals should be informed of this risk.
- 4 May 2022
- Published by Springer Nature in Diabetologia
- Vol. 65 (8) , 1278-1290
Insulin allergy: a diagnostic and therapeutic strategy based on a retrospective cohort and a case–control study
Aims/hypothesis Insulin allergy is a rare but significant clinical challenge. We aimed to develop a management workflow by (1) validating clinical criteria to guide diagnosis, based on a retrospective cohort, and (2) assessing the diagnostic performance of confirmatory tests, based on a case–control study. Methods In the retrospective cohort, patients with suspected insulin allergy were classified into three likelihood categories according to the presence of all (likely insulin allergy; 26/52, 50%), some (possible insulin allergy; 9/52, 17%) or none (unlikely insulin allergy; 17/52, 33%) of four clinical criteria: (1) recurrent local or systemic immediate or delayed hypersensitivity reactions; (2) reactions elicited by each injection; (3) reactions centred on the injection sites; and (4) reactions observed by the investigator (i.e. in response to an insulin challenge test). All underwent intradermal reaction (IDR) tests. A subsequent case–control study assessed the diagnostic performance of IDR, skin prick and serum anti-insulin IgE tests in ten clinically diagnosed insulin allergy patients, 24 insulin-treated non-allergic patients and 21 insulin-naive patients. Results In the retrospective cohort, an IDR test validated the clinical diagnosis in 24/26 (92%), 3/9 (33%) and 0/14 (0%) likely, possible and unlikely insulin allergy patients, respectively. In the case–control study, an IDR test was 80% sensitive and 100% specific and identified the index insulin(s). The skin prick and IgE tests had a marginal diagnostic value. Patients with IDR-confirmed insulin allergy were treated using a stepwise strategy. Conclusions/interpretation Subject to validation, clinical likelihood criteria can effectively guide diabetologists towards an insulin allergy diagnosis before undertaking allergology tests. An IDR test shows the best diagnostic performance. A progressive management strategy can subsequently be implemented. Continuous subcutaneous insulin infusion is ultimately required in most patients. ClinicalTrials.gov: NCT01407640. Graphical abstract
- 4 May 2022
- Published by Springer Nature in Diabetologia
- Vol. 65 (8) , 1278-1290
Insulin allergy: a diagnostic and therapeutic strategy based on a retrospective cohort and a case–control study
Aims/hypothesis Insulin allergy is a rare but significant clinical challenge. We aimed to develop a management workflow by (1) validating clinical criteria to guide diagnosis, based on a retrospective cohort, and (2) assessing the diagnostic performance of confirmatory tests, based on a case–control study. Methods In the retrospective cohort, patients with suspected insulin allergy were classified into three likelihood categories according to the presence of all (likely insulin allergy; 26/52, 50%), some (possible insulin allergy; 9/52, 17%) or none (unlikely insulin allergy; 17/52, 33%) of four clinical criteria: (1) recurrent local or systemic immediate or delayed hypersensitivity reactions; (2) reactions elicited by each injection; (3) reactions centred on the injection sites; and (4) reactions observed by the investigator (i.e. in response to an insulin challenge test). All underwent intradermal reaction (IDR) tests. A subsequent case–control study assessed the diagnostic performance of IDR, skin prick and serum anti-insulin IgE tests in ten clinically diagnosed insulin allergy patients, 24 insulin-treated non-allergic patients and 21 insulin-naive patients. Results In the retrospective cohort, an IDR test validated the clinical diagnosis in 24/26 (92%), 3/9 (33%) and 0/14 (0%) likely, possible and unlikely insulin allergy patients, respectively. In the case–control study, an IDR test was 80% sensitive and 100% specific and identified the index insulin(s). The skin prick and IgE tests had a marginal diagnostic value. Patients with IDR-confirmed insulin allergy were treated using a stepwise strategy. Conclusions/interpretation Subject to validation, clinical likelihood criteria can effectively guide diabetologists towards an insulin allergy diagnosis before undertaking allergology tests. An IDR test shows the best diagnostic performance. A progressive management strategy can subsequently be implemented. Continuous subcutaneous insulin infusion is ultimately required in most patients. ClinicalTrials.gov: NCT01407640. Graphical abstract
- Open Access
- 1 April 2021
- Published by Springer Nature in Research Square
Collider and Reporting Biases Involved in the Analyses of Cause of Death Associations in Death Certificates: an Illustration with Cancer and Suicide
Background: Data from death certificates have been studied to explore causal associations between diseases. However, these analyses are subject to collider and reporting biases (selection and information biases, respectively). Methods: We aimed to assess to what extent associations of causes of death estimated from individual mortality data can be extrapolated to the general population. We used a multistate model to generate populations of individuals and simulate their health states up to death from national health statistics and artificially replicate collider bias. Associations between health states can then be estimated from such simulated deaths by logistic regression and the magnitude of collider bias assessed. Reporting bias can be approximated by comparing the estimates obtained from the observed death certificates (subject to collider and reporting biases) with those obtained from the simulated deaths (subject to collider bias only). Results: As an illustrative example, we estimated the association between cancer and suicide in French death certificates, and found that cancer was negatively associated with suicide. Collider bias, due to conditioning inclusion in the study population on death, increasingly downwarded the associations with cancer site lethality. Reporting bias was much stronger than collider bias and depended on the cancer site, but not prognosis. Conclusions: These results argue for an assessment of the magnitude of both collider and reporting biases before performing analyses of cause of death associations exclusively from death certificates. If these biases cannot be corrected, results from these analyses should not be extrapolated to the general population.
- 1 April 2021
- Published by Springer Nature in Research Square
Open AccessCollider and Reporting Biases Involved in the Analyses of Cause of Death Associations in Death Certificates: an Illustration with Cancer and Suicide
Background: Data from death certificates have been studied to explore causal associations between diseases. However, these analyses are subject to collider and reporting biases (selection and information biases, respectively). Methods: We aimed to assess to what extent associations of causes of death estimated from individual mortality data can be extrapolated to the general population. We used a multistate model to generate populations of individuals and simulate their health states up to death from national health statistics and artificially replicate collider bias. Associations between health states can then be estimated from such simulated deaths by logistic regression and the magnitude of collider bias assessed. Reporting bias can be approximated by comparing the estimates obtained from the observed death certificates (subject to collider and reporting biases) with those obtained from the simulated deaths (subject to collider bias only). Results: As an illustrative example, we estimated the association between cancer and suicide in French death certificates, and found that cancer was negatively associated with suicide. Collider bias, due to conditioning inclusion in the study population on death, increasingly downwarded the associations with cancer site lethality. Reporting bias was much stronger than collider bias and depended on the cancer site, but not prognosis. Conclusions: These results argue for an assessment of the magnitude of both collider and reporting biases before performing analyses of cause of death associations exclusively from death certificates. If these biases cannot be corrected, results from these analyses should not be extrapolated to the general population.
- Open Access
- 1 January 2021
- Published by OpenEdition in Revue internationale de pédagogie de l’enseignement supérieur
- Vol. 37 (3)
Formation interdisciplinaire à la pédagogie dans l’enseignement supérieur : de l’expérience individuelle à la dynamique collective pour impulser une transformation pédagogique
Cet article est le fruit d'une collaboration réflexive de cinq enseignants de champs disciplinaires et de structures universitaires différents, avec l’aide de deux conseillères pédagogiques. Il s'agit d'un retour d'expérience à la suite de la participation de ces enseignants à un parcours de formation à la pédagogie universitaire intitulé CertifiENS. Notre propos est surtout de témoigner de cette expérience originale et interdisciplinaire, en décrivant les caractéristiques de notre groupe d’enseignants, le parcours CertifiENS que nous avons suivi puis les transformations pédagogiques que nous avons opérées dans nos enseignements. Nous avons sollicité a posteriori deux de nos conseillères pédagogiques (formatrices dans le cadre du parcours CertifiENS et enseignantes-chercheuses en sociologie et sciences de l’éducation) pour un entretien de groupe (focus group) visant à expliciter nos intentions et motivations initiales et mettre en lumière l'émergence d'une dynamique collective. Cet entretien de groupe nous a permis de porter une analyse réflexive individuelle puis collective sur le processus de transformation individuelle et sur la transition pédagogique effectuée et toujours en devenir.Cette analyse a montré que l’interdisciplinarité a été un atout majeur et une source de synergies, permettant de nous focaliser sur le commun : la pédagogie. Le groupe a été porteur d’une transformation durable des pratiques enseignantes, chacun sur son terrain respectif a souhaité continuer à porter ce changement de paradigme, tout en réfléchissant à la construction d’une communauté de pratiques.
- 1 January 2021
- Published by OpenEdition in Revue internationale de pédagogie de l’enseignement supérieur
- Vol. 37 (3)
Open AccessFormation interdisciplinaire à la pédagogie dans l’enseignement supérieur : de l’expérience individuelle à la dynamique collective pour impulser une transformation pédagogique
Cet article est le fruit d'une collaboration réflexive de cinq enseignants de champs disciplinaires et de structures universitaires différents, avec l’aide de deux conseillères pédagogiques. Il s'agit d'un retour d'expérience à la suite de la participation de ces enseignants à un parcours de formation à la pédagogie universitaire intitulé CertifiENS. Notre propos est surtout de témoigner de cette expérience originale et interdisciplinaire, en décrivant les caractéristiques de notre groupe d’enseignants, le parcours CertifiENS que nous avons suivi puis les transformations pédagogiques que nous avons opérées dans nos enseignements. Nous avons sollicité a posteriori deux de nos conseillères pédagogiques (formatrices dans le cadre du parcours CertifiENS et enseignantes-chercheuses en sociologie et sciences de l’éducation) pour un entretien de groupe (focus group) visant à expliciter nos intentions et motivations initiales et mettre en lumière l'émergence d'une dynamique collective. Cet entretien de groupe nous a permis de porter une analyse réflexive individuelle puis collective sur le processus de transformation individuelle et sur la transition pédagogique effectuée et toujours en devenir.Cette analyse a montré que l’interdisciplinarité a été un atout majeur et une source de synergies, permettant de nous focaliser sur le commun : la pédagogie. Le groupe a été porteur d’une transformation durable des pratiques enseignantes, chacun sur son terrain respectif a souhaité continuer à porter ce changement de paradigme, tout en réfléchissant à la construction d’une communauté de pratiques.
- 1 September 2020
- Published by Elsevier in Journal of Affective Disorders
- Vol. 274, 174-182
Contacts with Health Services During the Year Prior to Suicide Death and Prevalent Conditions A Nationwide Study
- 1 September 2020
- Published by Elsevier in Journal of Affective Disorders
- Vol. 274, 174-182
Contacts with Health Services During the Year Prior to Suicide Death and Prevalent Conditions A Nationwide Study
- 6 March 2020
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 115 (4) , 537-547
Incidence of and Risk Factors for Systemic Adverse Events After Screening or Primary Diagnostic Colonoscopy: A Nationwide Cohort Study
OBJECTIVES: To estimate the systemic serious adverse event (SAE) rates after colonoscopy and to identify their risk factors. METHODS: A nationwide cohort study was conducted using the comprehensive French claims databases SNDS (National Health Data System). Patients aged 30 years and over who underwent a first screening or diagnostic colonoscopy in 2010–2015 were included. The rates of cardiovascular and renal SAEs were estimated within 5 days after colonoscopy. The standardized incidence ratios were calculated to compare these incidence rates with those of the same events in the general population, and the associated risk factors were assessed by multilevel logistic regression. RESULTS: Among the 4,088,799 included patients (median age, 59 years [interquartile range = 50–67]; 55.2% women; 30.1% with a Charlson index score ≤1), the 5-day SAE incidence rate was 2.8/10,000 procedures for shock, 0.87/10,000 for myocardial infarction, 1.9/10,000 for stroke, 2.9/10,000 for pulmonary embolism, 5.5/10,000 for acute renal failure, and 3.3/10,000 for urolithiasis. These SAEs occurred 3.3 to 15.8 times more often during the first 5 days after colonoscopy than expected in the general population. Thirty-day mortality rates ranged from 2.2/1,000 cases of urolithiasis to 268.1/1,000 cases of shock. Increasing age was associated with an increasing incidence of SAEs. Risks of shock and acute renal failure were associated with a greater number of comorbidities than the other SAEs. Colonoscopies in university hospitals were associated with higher risks, reflecting patient selection processes. DISCUSSION: The systemic SAEs can be associated with a substantial mortality. They should be taken into account when deciding colonoscopy, in addition to perforation and bleeding, particularly in elderly patients with multiple comorbidities.
- 6 March 2020
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 115 (4) , 537-547
Incidence of and Risk Factors for Systemic Adverse Events After Screening or Primary Diagnostic Colonoscopy: A Nationwide Cohort Study
OBJECTIVES: To estimate the systemic serious adverse event (SAE) rates after colonoscopy and to identify their risk factors. METHODS: A nationwide cohort study was conducted using the comprehensive French claims databases SNDS (National Health Data System). Patients aged 30 years and over who underwent a first screening or diagnostic colonoscopy in 2010–2015 were included. The rates of cardiovascular and renal SAEs were estimated within 5 days after colonoscopy. The standardized incidence ratios were calculated to compare these incidence rates with those of the same events in the general population, and the associated risk factors were assessed by multilevel logistic regression. RESULTS: Among the 4,088,799 included patients (median age, 59 years [interquartile range = 50–67]; 55.2% women; 30.1% with a Charlson index score ≤1), the 5-day SAE incidence rate was 2.8/10,000 procedures for shock, 0.87/10,000 for myocardial infarction, 1.9/10,000 for stroke, 2.9/10,000 for pulmonary embolism, 5.5/10,000 for acute renal failure, and 3.3/10,000 for urolithiasis. These SAEs occurred 3.3 to 15.8 times more often during the first 5 days after colonoscopy than expected in the general population. Thirty-day mortality rates ranged from 2.2/1,000 cases of urolithiasis to 268.1/1,000 cases of shock. Increasing age was associated with an increasing incidence of SAEs. Risks of shock and acute renal failure were associated with a greater number of comorbidities than the other SAEs. Colonoscopies in university hospitals were associated with higher risks, reflecting patient selection processes. DISCUSSION: The systemic SAEs can be associated with a substantial mortality. They should be taken into account when deciding colonoscopy, in addition to perforation and bleeding, particularly in elderly patients with multiple comorbidities.
- 1 November 2019
- Published by Oxford University Press (OUP) in European Journal of Public Health
- Vol. 29 (Supplement)
Factors associated with mechanical and systemic adverse events after colonoscopy (France, 2010-2015)
Background: More than one million colonoscopies are performed every year in France. They are associated with risks of mechanical and systemic serious adverse events (SAEs) which can be associated with patient, procedure, endoscopist, and facility characteristics. We tried to identify the factors associated with colonic perforation, gastrointestinal bleeding, splenic injury, shock, myocardial infarction, stroke, pulmonary embolism, acute renal failure, and urolithiasis after colonoscopy. Methods: We analysed data from the French national claims databases (SNDS). A total of 4,088,799 patients, 30 years or older, undergoing a first screening or diagnostic colonoscopy between 2010 and 2015 were identified. SAE rates were estimated, and risk factors associated with SAEs were identified using multilevel logistic regression models, adjusted for patient, colonoscopy, endoscopist, and facility characteristics. Results: Increasing age was associated with an increasing incidence of mechanical and systemic SAEs. Cancer and cardiovascular comorbidities were associated with mechanical SAEs, and a higher number of pre-existing conditions was associated with shock and acute renal failure. Polypectomy, especially of polyps larger than 1 cm, was associated with an increased risk of perforation (OR = 4.1; 95% CI, 3.4-5.0) and bleeding (OR = 13.3; 95% CI, 11.7-15.1). Mechanical SAEs were associated with the endoscopist’s experience, while systemic SAEs were more frequent in public hospitals than in private clinics. Conclusions: SAEs related to colonoscopy were more frequent in older patients and in those with comorbidities. Mechanical SAEs were more frequent when colonoscopy was performed by less experienced endoscopists. Systemic SAEs were more frequent in public hospitals, reflecting patient selection processes. The risk of both mechanical and systemic SAEs should be taken into account when deciding to perform colonoscopy, particularly in older patients with multiple pre-existing conditions. Key messages: Systemic SAEs are not uncommon after colonoscopy and, together with intestinal SAEs, should be considered when considering the need for colonoscopy. Patients at risk of SAEs should be identified and colonoscopy should be performed by experienced endoscopists in these patients. Less invasive alternatives should also be considered in these patients.
- 1 November 2019
- Published by Oxford University Press (OUP) in European Journal of Public Health
- Vol. 29 (Supplement)
Factors associated with mechanical and systemic adverse events after colonoscopy (France, 2010-2015)
Background: More than one million colonoscopies are performed every year in France. They are associated with risks of mechanical and systemic serious adverse events (SAEs) which can be associated with patient, procedure, endoscopist, and facility characteristics. We tried to identify the factors associated with colonic perforation, gastrointestinal bleeding, splenic injury, shock, myocardial infarction, stroke, pulmonary embolism, acute renal failure, and urolithiasis after colonoscopy. Methods: We analysed data from the French national claims databases (SNDS). A total of 4,088,799 patients, 30 years or older, undergoing a first screening or diagnostic colonoscopy between 2010 and 2015 were identified. SAE rates were estimated, and risk factors associated with SAEs were identified using multilevel logistic regression models, adjusted for patient, colonoscopy, endoscopist, and facility characteristics. Results: Increasing age was associated with an increasing incidence of mechanical and systemic SAEs. Cancer and cardiovascular comorbidities were associated with mechanical SAEs, and a higher number of pre-existing conditions was associated with shock and acute renal failure. Polypectomy, especially of polyps larger than 1 cm, was associated with an increased risk of perforation (OR = 4.1; 95% CI, 3.4-5.0) and bleeding (OR = 13.3; 95% CI, 11.7-15.1). Mechanical SAEs were associated with the endoscopist’s experience, while systemic SAEs were more frequent in public hospitals than in private clinics. Conclusions: SAEs related to colonoscopy were more frequent in older patients and in those with comorbidities. Mechanical SAEs were more frequent when colonoscopy was performed by less experienced endoscopists. Systemic SAEs were more frequent in public hospitals, reflecting patient selection processes. The risk of both mechanical and systemic SAEs should be taken into account when deciding to perform colonoscopy, particularly in older patients with multiple pre-existing conditions. Key messages: Systemic SAEs are not uncommon after colonoscopy and, together with intestinal SAEs, should be considered when considering the need for colonoscopy. Patients at risk of SAEs should be identified and colonoscopy should be performed by experienced endoscopists in these patients. Less invasive alternatives should also be considered in these patients.